Plain-English translation of NCT06523556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a medication called to treat certain advanced blood cancers, including chronic myelomonocytic leukemia and related conditions. The trial will test the medication either alone or combined with , another cancer drug. Researchers want to find the right dose and understand how well this medication works for people whose disease has not responded to prior treatments or who have been newly diagnosed.
People with these advanced blood cancers often run out of treatment options, and available therapies don't work for everyone. This trial is exploring whether this medication could offer a new option for patients who need better treatments.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the medication every 2 weeks (on days 1 and 15 of each 28-day cycle). Depending on how you respond, you may be in the first phase of the trial (testing the medication alone) or move to the second phase (combining it with ). Throughout the study, you'll have blood tests and possibly bone marrow biopsies to monitor how the treatment is working. Treatment may continue for up to 24 cycles (about 2 years) if you're responding well.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States